@article{f019bfbc07274eac97ae03d642e857f8,
title = "Hereditary endocrine tumours: Current state-of-the-art and research opportunities: MEN1-related pancreatic NETs: Identification of unmet clinical needs and future directives",
abstract = "The PanNET Working Group of the 16th International Multiple Endocrine Neoplasia Workshop (MEN2019) convened in Houston, TX, USA, 27-29 March 2019 to discuss key unmet clinical needs related to PanNET in the context of MEN1, with a special focus on non-functioning (nf)-PanNETs. The participants represented a broad range of medical scientists as well as representatives from patient organizations, pharmaceutical industry and research societies. In a case-based approach, participants addressed early detection, surveillance, prognostic factors and management of localized and advanced disease. For each topic, after a review of current evidence, key unmet c linical needs and future research directives to make meaningful progress for MEN1 patients with nf-PanNETs were identified. International multi-institutional collaboration is needed for adequately sized studies and validation of findings in independent datasets. Collaboration between basic, translational and clinical scientists is paramount to establishing a translational science approach. In addition, bringing clinicians, scientists and patients together improves the prioritization of research goals, assures a patient-centered approach and maximizes patient involvement. It was concluded that collaboration, research infrastructure, methodologic and reporting rigor are essential to any translational science effort. The highest priority for nf-PanNETs in MEN1 syndrome are (1) the development of a data and biospecimen collection architecture that is uniform across all MEN1 centers, (2) unified strategies for diagnosis and follow-up of incident and prevalent nf-PanNETs, (3) non-invasive detection of individual nf-PanNETs that have an increased risk of metastasis, (4) chemoprevention clinical trials driven by basic research studies and (5) therapeutic targets for advanced disease based on biologically plausible mechanisms.",
keywords = "Conference proceeding, MEN1, Management, Management, Multiple endocrine neoplasia type 1, Pancreatic neuroendocrine tumor, Research infrastructure, Risk stratification, Surveillance, Treatment, Unmet clinical needs",
author = "Pieterman, \{C. R.C.\} and Sadowski, \{S. M.\} and Maxwell, \{J. E.\} and Katz, \{M. H.G.\} and Lines, \{K. E.\} and Heaphy, \{C. M.\} and A. Tirosh and Blau, \{J. E.\} and Perrier, \{N. D.\} and Lewis, \{M. A.\} and Metzcar, \{J. P.\} and Halperin, \{D. M.\} and Thakker, \{R. V.\} and Valk, \{G. D.\}",
note = "Publisher Copyright: {\textcopyright} 2020 Society for Endocrinology Published by Bioscientifica Ltd. Printed in Great Britain.",
year = "2020",
month = aug,
doi = "10.1530/ERC-19-0441",
language = "אנגלית",
volume = "27",
pages = "T9--T25",
journal = "Endocrine-Related Cancer",
issn = "1351-0088",
publisher = "BioScientifica Ltd.",
number = "8",
}